

Engagement Opportunities

Welcome Reception – Get a taste of Indy and engage with your colleagues as you help kick off CPNP 2018 at the Sunday night reception.

Cutting-Edge Research – Gain insights from 240+ peer-reviewed, research and practice posters and benefit from three hours of uninterrupted networking with poster authors on Monday and Tuesday as you further explore presented research, innovative practices, and case management.

Discussion Dens – Benefit from peer-to-peer dialogue through informal sessions led by CPNP Communities on topics of importance today and to the future of the profession and patient care.

Fight Stigma – Band with your colleagues to fight stigma by participating in various events sponsored by the CPNP Foundation including the annual NAMI Walk.

And More! Take advantage of 6+ hours of dedicated networking time to share information and solutions with colleagues throughout CPNP 2018.

Resident and Student Programming Tracks

Residents and students can take advantage of programming geared specifically to them. While residents glean insights into what it takes to start a new service and navigate the transition to new practitioner status, students learn how to compete and prepare for residencies all while gaining exposure to the types of practice available to psychiatric pharmacists. Both residents and students may also participate in CPNP Connect, a mentoring opportunity with CPNP members.

Meeting Site and Reservations

The **JW Marriott Indianapolis**, the host site for CPNP 2018, is uniquely situated between Downtown Indy and White River State Park. The city’s internationally-acclaimed, 8-mile Cultural Trail allows visitors to easily explore the city while enjoying many shopping, dining, and entertainment options. Indianapolis International Airport is located just 12 miles from the host hotel and transportation is made easy with Uber, Lyft, and the GO Green Shuttle. Make your hotel reservations for the JW Marriott online at <https://aws.passkey.com/go/CPNPAttendee> or call 1-866-704-6162. With several events in Indy, the room block is filling fast, so act quickly.

Room Rates*

Regular: \$194/night + taxes

Student: \$160/night + taxes
(limited number of rooms available at this rate)

**Room rates available until 3/29/18 or until the room block is filled*

Early Bird Registration Fees
(through 3/22/2018 – see cpnp.org/register)

	Member	Non-member
Pre-Meeting Workshop	\$115	\$140
Pharmacist Full Registration	\$525	\$700
Fellow/Resident Full Registration	\$285	\$385
Student Full Registration	\$175	\$225

Single day and numerous other registration options available online.

Register at cpnp.org/register
Member pricing available with a 6-month trial at cpnp.org/join



College of Psychiatric
& Neurologic Pharmacists

cpnp

8055 O Street, Ste. S113
Lincoln, NE 68510

#CPNP2018
where pharmacy and psychiatry meet

Goals and Target Audience

The CPNP Annual Meeting is the premier meeting devoted to advancing the practice of psychiatric pharmacists in the context of a rapidly changing healthcare environment. The meeting provides cutting-edge educational programming, opportunities for active participation, and idea exchange through community meetings, forums, poster sessions, networking opportunities, and member-driven content. Programming includes focused sessions designed to develop specific skills and knowledge on healthcare issues and disease states impacting psychiatric pharmacy practice. Health professionals engaged in the care of patients with psychiatric, neurologic, and/or substance use disorders will find this meeting to be an educational and enlightening experience that positively impacts their daily practice.




ATTEND
THE PREMIER
CONFERENCE ON
PSYCHOPHARMACOLOGY!

Save the Date
for CPNP 2019
April 7-10,
Salt Lake City, UT

VISIT cpnp.org/2018 for more information

#CPNP2018
where pharmacy and psychiatry meet

ADVANCING THE
SPECTRUM
OF PATIENT CARE



April 22-25, 2018
JW Marriott
Indianapolis, Indiana



cpnp.org/2018

PRE-MEETING WORKSHOP

Creative and Collaborative: Pharmacists on the Front-line of Medication Assisted Treatment for Opioid Use Disorder

Sunday, April 22 • 7:45–11:30 AM

Pharmacists are underutilized, accessible, and essential healthcare providers who are trained to recognize opioid overdose, opioid use disorder, and withdrawal syndromes. Integration of the pharmacist into medication assisted treatment (MAT) teams for opioid use disorders can help improve access and outcomes, while reducing the risk of relapse. When pharmacists partner with prescribers to provide MAT, pharmacists are able to take the lead in identifying treatment options, developing treatment plans, communicating with patients, improving adherence, monitoring patients, and performing tasks to alleviate prescriber burden.

This session will showcase different practice settings where psychiatric pharmacists partner with prescribers to provide collaborative care for patients with substance use disorders. The learner will leave with knowledge of innovative ways to include pharmacists on the MAT interprofessional team and how to design and execute effective practice protocols. In addition, the learner will explore the pharmacist's role in addressing controversies and challenges in providing MAT with regard to state and federal level limitations. From this workshop you will be able to:

- 1 Evaluate the need and capacity for medication assisted treatment for opioid use disorder on the state and national levels.
- 2 Compare outcomes from collaborations integrating pharmacists in the medication assisted treatment care team in different practice settings across the United States.
- 3 Describe the barriers and benefits encountered in establishing a collaborative practice agreement with prescribers to provide medication assisted treatment.
- 4 Engage legislators, state administrators, and professional organizations to promote the role of pharmacists in medication assisted treatment.

Speakers



Sarah Melton, PharmD, BCPP, BCACP, BCGP, FASCP
Workshop Chair
Professor of Pharmacy Practice
Gatton College of Pharmacy at East Tennessee State University
Clinical Pharmacist, Johnson City Community Health Center



Gayle Callahan, PharmD, BCPP
Substance Use Disorder/Mental Health Consultant Pharmacist
Operation PAR



Bethany DiPaula, PharmD, BCPP
Associate Professor, University of Maryland
Director of Pharmacy, Springfield Hospital Center



Christopher M. Jones, PharmD, MPH
Director of the National Mental Health and Substance Use Policy Laboratory
Substance Abuse and Mental Health Services Administration (SAMHSA)



Raymond Love, PharmD, BCPP, FASHP
Professor of Pharmacy
Vice Chair for the Department of Pharmacy Practice and Science
Director Mental Health Program, University of Maryland



Troy Moore, PharmD, MS, BCPP
Clinical Pharmacy Specialist, South Texas Veterans Health Care System
Assistant Professor, University of Texas

Registration Fee

The registration fee includes 3.5 contact hours of ACPE credit, learning materials, interactive/practical application experiences, and break service.

KEYNOTE ADDRESSES

America's Opioid Crisis and the Role of Pharmacists

Monday, April 23 • 8:30-9:30 AM



Christopher M. Jones, PharmD, MPH

Join Dr. Christopher M. Jones, Director of the National Mental Health and Substance Use Policy Laboratory at the Substance Abuse and Mental Health Services Administration (SAMHSA), as he describes how the misuse of and addiction to opioids is a serious national problem that affects public health, as well as social and economic welfare. Jones will address the opioid crisis in the United States, the rising incidence of neonatal abstinence syndrome (due to opioid use during pregnancy), and the increased spread of infectious diseases, including HIV and hepatitis C. Primary approaches to addressing the crisis include prevention, addressing the underlying addiction issues, and treating overdoses directly by increasing access to naloxone. Longer-term research includes the development of pain medications with reduced abuse/addiction potential. In addition, the ways that pharmacists can play central roles in changing prescribing practices, increasing access to naloxone, and improving access to methadone and buprenorphine with pharmacy dispensing will be reviewed.



Michael E. Thase, MD

Mixed Opinions: Recognition and Management of Mixed Depression

Monday, April 23 • 9:30-10:30 AM

The current DSM-5 manual includes a new specifier for mixed features; however, there are no Food and Drug Administration-approved medications to treat major depressive disorder with mixed features. Furthermore, there are two guidelines that provide decision support to providers managing patients with depression with mixed features. Importantly, these guidelines differ in their recommendations namely whether to use antidepressant monotherapy due to the potential risk for inducing a treatment emergent affective switch. Pharmacists involved in management of patients with depressive mixed episodes can provide valuable input to the healthcare team by understanding available data as well as how to best manage this patient population. This program will improve pharmacists' knowledge of the mixed features specifier and depressive mixed states presentation including common differential diagnoses as well as inform pharmacists on evidence-based treatment options for these patients..



Deanna L. Kelly, PharmD, BCPP

Gluten Sensitivity in Schizophrenia

Tuesday, April 24 • 8:30-9:30 AM

Deconstructing the illness of schizophrenia is of particular interest as this heterogeneous disorder may be composed of etiologically distinct disorders with different mechanisms which could all serve as treatment targets for components of the disorder. One specific group with elevated peripheral and central inflammatory response is those with schizophrenia having elevations in anti gliadin antibodies (AGA IgG). In addition to high inflammation, this subgroup may be distinct by having lower positive symptoms and high kynurenic acid levels. This population may represent a subgroup which may have personalized and targeted treatments developed. This talk will discuss the emerging association of inflammation and immune activity in schizophrenia, review the data that helps characterize the subgroup with AGA IgG, and present ongoing work for treatment targets and mechanisms of action connecting gluten to schizophrenia. This work suggests that more personalized treatments targeting diet modulation or immune/inflammation may play future roles in schizophrenia treatment.



Richard S.E. Keefe, PhD

Cognitive Deficits in Schizophrenia

Tuesday, April 24 • 9:45-10:45 AM

Cognitive deficits in schizophrenia such as problems with attention, memory, and processing speed, lead to important difficulties in social and occupational function for the patients who suffer from the illness. Dr. Richard Keefe will assess the unmet needs related to cognitive function in schizophrenia, describe the methods used to assess these important deficits, and review the treatments currently employed to treat them. Filling an important gap in pharmacy education, cutting-edge strategies will be discussed that relate to both behavioral interventions and pharmacological interventions to improve these important symptoms. Agents in the pipeline with promising data will also be described.

CPNP 2018 AT A GLANCE

PRE-MEETING WORKSHOP	
Creative and Collaborative: Pharmacists on the Front-line of Medication Assisted Treatment for Opioid Use Disorder	Sarah Melton, PharmD, BCPP, BCACP, BCGP, FASCP , Professor of Pharmacy Practice, Gatton College of Pharmacy, Johnson City, TN Speakers and Panelists: Gayle Callahan, PharmD, BCPP; Bethany DiPaula, PharmD, BCPP; Christopher M. Jones, PharmD, MPH; Ray Love, PharmD, BCPP, FASHP; Troy Moore, PharmD, MS, BCPP
KEYNOTE ADDRESSES	
America's Opioid Crisis and the Role of Pharmacists	Christopher M. Jones, PharmD, MPH , Director of the National Mental Health and Substance Use Policy Laboratory at the Substance Abuse and Mental Health Services Administration (SAMHSA), Washington, D.C.
Mixed Opinions: Recognition and Management of Mixed Depression	Michael E. Thase, MD , Professor of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Gluten Sensitivity in Schizophrenia	Deanna Kelly, PharmD, BCPP , Professor, University of Maryland, Baltimore, MD
Cognitive Deficits in Schizophrenia	Richard Keefe, PhD , Professor of Psychiatry, Psychology and Neuroscience, Duke University Medical Center, Durham, NC
BCPP RECERTIFICATION SESSIONS 	
Painfully Sleepless: Treatment of Sleep Disturbances in Fibromyalgia	Christopher Herndon, PharmD, BCPS, CPE, FASHP , Associate Professor, Southern Illinois University Edwardsville (SIUE) School of Pharmacy; Clinical Associate Professor, St. Louis University School of Medicine, Edwardsville, IL
Identification and Management of Delirium in the Elderly	Dora Cheung, PharmD, BCPS, BCGP , Clinical Pharmacy Specialist – Internal Medicine & Geriatrics, University of Colorado Hospital, Denver, CO
Cognitive Behavioral Therapy for Psychosis	Harry Sivec, PhD , Psychologist, Northeast Ohio Medical University, Rootstown, OH
Current Controversies with Psychotropic Use in Pregnancy	Marlene Freeman, MD , Associate Professor of Psychiatry, Harvard Medical School; Associate Director, Perinatal and Reproductive Psychiatry Program; Medical Director, Clinical Trials Network and Institute, Boston, MA
A Complicated Relationship: Depression, Insomnia, and Hepatitis C	Susie H. Park, PharmD, BCPP, FCSHP , Associate Professor of Clinical Pharmacy and Pharmaceutical Economics and Policy, University of Southern California School of Pharmacy, Los Angeles, CA
GENERAL SESSIONS	
QTc Interval Prolongation: Clinical Relevance, Prevention, and Management	James Tisdale, PharmD, FCCP, FAPhA, FNAP, FAHA , Professor, College of Pharmacy, Purdue University and School of Medicine, Indiana University, Indianapolis, IN
Why Gliat Cells Hurt: Talking to Patients About Chronic Pain	Lee Kral, PharmD, BCPS , Clinical Pharmacy Specialist - Pain Management, The University of Iowa Hospitals & Clinics, Iowa City, IA
When Less is More: Rational Deprescribing	Barbara Farrell, BScPhm, PharmD, FCSHP , Scientist, Bruyere Research Institute and CT Lamont Primary Health Care Research Centre; Pharmacist, Geriatric Day Hospital, Bruyere Continuing Care; Assistant Professor, Department of Family Medicine, University of Ottawa, Ontario, Canada
The Emerging Role of Neuromodulation Therapies for Psychiatric Disorders: A Focus on Transcranial Magnetic Stimulation for Treatment-Resistant Depression	Philip Janicak, MD , Adjunct Professor, Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL
CONCURRENT SESSIONS	
Beyond Psychosis: Understanding Bipolar At-Risk Youth and Prodromal States in Bipolar Disorder	Boris Birmaher, MD , Professor of Psychiatry, University of Pittsburgh, Pittsburgh, PA
Blast from the Past: Practical Considerations for Safe Use of Monoamine Oxidase Inhibitors (MAOIs) and Lithium	Patrick Finley, PharmD, BCPP , Professor of Clinical Pharmacy, University of California, San Francisco, CA
Menopausal Depression	Marlene Freeman, MD , Associate Professor of Psychiatry, Harvard Medical School; Associate Director, Perinatal and Reproductive Psychiatry Program; Medical Director, Clinical Trials Network and Institute, Boston, MA
Everything You Wanted to Know About Older Adults with Bipolar Disorder	Martha Sajatovic, MD , Professor of Psychiatry and of Neurology; Director, Neurological and Behavioral Outcomes Center, University Hospitals Cleveland Medical Center, Cleveland, OH
Old Dog, New Tricks: Innovative Therapies for Schizophrenia	Alan Breier, MD , Senior Professor of Psychiatry; Vice-Chair for Clinical Research Chief; Psychotic Disorders Program Director, Prevention and Recovery Center, Indiana University School of Medicine, Indianapolis, IN
Treatment of the Patient with Refractory Seizures	James Cloyd III, PharmD , Professor and Lawrence C. Weaver Endowed Chair-Orphan Drug Development, University of Minnesota College of Pharmacy, Minneapolis, MN
The Pharmacist in Recovery: Stories of Resilience and Hope	Brian Fingerson, BS Pharm, RPh, FAPhA , President, Kentucky Professionals Recovery Network, Louisville, KY
Fitting the Right Disease: Modifying Therapy to the Patient with Multiple Sclerosis	Jacquelyn Bainbridge, PharmD , Professor, Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO
Struggles with Urine Drug Screens	Karen Moeller, PharmD, BCPP , Clinical Associate Professor, The University of Kansas School of Pharmacy, Lawrence, KS

 The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The 2018 Annual Meeting will provide up to 16 contact hours of knowledge-based and application-based continuing education credit from CPNP approved programming. The pre-meeting workshop is provided for an additional 3.5 contact hours and when combined with all other CPNP programming, allows for a maximum achievable 19.5 contact hours. Industry supported symposia offered at the Annual Meeting offer additional ACPE credit.